News

June 27, 2017

Mutation That Interferes with Genetic Instructions May Cause Hereditary ALS, Study Reports

News

Harvard Medical School researchers have discovered how a mutation of the C9ORF72 gene causes the changes in energy production and nerve cell function that are linked to inherited forms ... Read more

June 26, 2017

Level of Neurofilaments in Cerebrospinal Fluid Could Confirm ALS Diagnosis, Study Reports

News

Measuring neurofilaments in brain and spinal fluid appears to be a reliable way of confirming an ALS diagnosis, Belgian and German researchers report. This finding is important because it takes ... Read more

June 23, 2017June 23, 2017

Israel’s BrainStorm Receives $2.1 Million Grant to Support Development of Stem-Cell Therapy NurOwn to Treat ALS

News

The Israel Innovation Authority (IIA) has awarded BrainStorm Cell Therapeutics a $2.1 million grant to support the development of NurOwn, an innovative mesenchymal stem cell-based platform to treat neurodegenerative diseases including amyotrophic ... Read more

June 22, 2017June 22, 2017

Metal Levels in Blood, Urine, and Hair May Serve as ALS Biomarkers, Study Suggests

News

Several metals may be linked to the risk of amyotrophic lateral sclerosis (ALS), according to results of a small study in Italy. The findings state that levels of metals and ... Read more

June 21, 2017June 21, 2017

Onetime Malaria Therapy Pyrimethamine Reduces Levels of ALS-linked Protein, Study Finds

News

The former malaria therapy pyrimethamine reduces levels of an ALS-linked protein in the spinal fluid of patients whose disease stems from gene mutations, a Phase 1/2 clinical trial shows. ... Read more

June 20, 2017

Clinical Trial Tests H.P. Acthar Gel as Potential ALS Treatment

News

Mallinckrodt has launched the Phase 2b PENNANT trial (NCT03068754) to investigate the safety and effectiveness of H.P. Acthar Gel (repository corticotropin injection) as a treatment for amyotrophic lateral sclerosis ... Read more

June 19, 2017

FDA Expands Approval of Dysport to Include Treatment of Lower-limb Adult Spasticity

News

The U.S. Food and Drug Administration has expanded its approval of Dysport (abobotulinumtoxinA) as a treatment for spasticity in adults from not just the upper limbs but to the lower ... Read more

June 16, 2017

Stem Cell Transplantation Shows Potential as ALS Therapy, Study Suggests

News

Stem cell transplantation in patients with amyotrophic lateral sclerosis (ALS) has the potential to be “an important alternative strategy” in treating the disease, a new study suggests. In recent decades, ... Read more

June 15, 2017June 15, 2017

ALS Patients Experience Inefficient Skeletal Muscle Oxidative Function During Exercise, Study Finds

News

A new study shows that patients with amyotrophic lateral sclerosis (ALS) experience decreased oxidative metabolism during exercise, and that differences among individuals in exercise capacity matches ALS clinical heterogeneity. ... Read more

June 14, 2017June 14, 2017

AveXis and REGENXBIO Sign Licensing Agreement to Develop Therapies for ALS and Rett syndrome

News

AveXis and REGENXBIO have signed a new licensing agreement to develop therapies for a particular form of ALS and for Rett syndrome. They already have an agreement that covers spinal muscular ... Read more